Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Hydrocodone | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Magnesium sulfate | The therapeutic efficacy of Gantacurium can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Gantacurium may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Mirtazapine | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Orphenadrine | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Pramipexole | Gantacurium may increase the sedative activities of Pramipexole. |
| Ropinirole | Gantacurium may increase the sedative activities of Ropinirole. |
| Rotigotine | Gantacurium may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Gantacurium. |
| Sodium oxybate | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Thalidomide | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Gantacurium. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Gantacurium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Gantacurium is combined with Botulinum toxin type B. |
| Ethanol | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Gantacurium may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Gantacurium. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Gantacurium is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Gantacurium is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Gantacurium is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Gantacurium is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Gantacurium is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Gantacurium is combined with Alaproclate. |
| Morphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Gantacurium is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Gantacurium is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Gantacurium is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Gantacurium is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Gantacurium is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Gantacurium is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Gantacurium is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Gantacurium is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Gantacurium is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Gantacurium is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Gantacurium is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Alphaprodine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Gantacurium is combined with Carfentanil, C-11. |
| Naltrexone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Gantacurium is combined with Bezitramide. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Gantacurium is combined with Nicomorphine. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Gantacurium is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Gantacurium is combined with Naloxegol. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Gantacurium. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Gantacurium. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Gantacurium. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Gantacurium. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Gantacurium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Gantacurium. |